NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic ...
Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.
Doctors should prescribe a sodium-glucose cotransporter-2 (SGLT-2) inhibitor alongside metformin to most patients with newly diagnosed type 2 diabetes, the National Institute for Health and Care ...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte ...
Medical Device Network on MSN
UK’s NICE greenlights Abbott’s CardioMEMS heart failure sensor
The implantable blood pressure sensor will now be available to patients with chronic heart failure through the NHS.
Abbott’s wireless, paperclip-sized cardiac sensor has received the blessing of Britain’s National Institute for Health and Care Excellence (NICE), paving the way for coverage of the device in ...
In its final draft guidance published on 24 October 2025, NICE approved darolutamide for adults with metastatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results